Influenza Infection in Ferrets with SARS-CoV-2 Infection History

During the COVID-19 pandemic, the use of face masks, social distancing, and isolation were effective not only in decreasing the circulation of SARS-CoV-2 but also in reducing other respiratory viruses, such as influenza. With fewer restrictions currently in place, influenza is slowly returning. ABSTRACT Nonpharmaceutical interventions (NPIs) to contain the SARS-CoV-2 pandemic drastically reduced human-to-human interactions, decreasing the circulation of other respiratory viruses, as well. Consequently, influenza virus circulation, which is normally responsible for 3 to 5 million hospitalizations per year globally, was significantly reduced. With the downscaling of the NPI countermeasures, there is a concern for increased influenza disease, particularly in individuals suffering from postacute effects of SARS-CoV-2 infection. To investigate this, we performed a sequential influenza H1N1 infection 4 weeks after an initial SARS-CoV-2 infection in ferrets. Upon H1N1 infection, ferrets that were previously infected with SARS-CoV-2 showed an increased tendency to develop clinical signs, compared to the control H1N1-infected animals. A histopathological analysis indicated only a slight increase for type II pneumocyte hyperplasia and bronchitis. Thus, the effects of the sequential infection appeared minor. However, ferrets were infected with B.1.351-SARS-CoV-2, the beta variant of concern, which replicated poorly in our model. The histopathology of the respiratory organs was mostly resolved 4 weeks after the SARS-CoV-2 infection, with only reminiscent histopathological features in the upper respiratory tract. Nevertheless, SARS-CoV-2 specific cellular and humoral responses were observed, confirming an established infection. On account of a modest trend toward the enhancement of the influenza disease, even upon a mild SARS-CoV-2 infection, our findings suggest that a stronger SARS-CoV-2 infection and its consequent, long-term effects could have a greater impact on the outcome of disease after a sequential influenza infection. Hence, the influenza vaccination of individuals suffering from postacute SARS-CoV-2 infection effects may be considered an avertible measure for such a scenario. IMPORTANCE During the COVID-19 pandemic, the use of face masks, social distancing, and isolation were effective not only in decreasing the circulation of SARS-CoV-2 but also in reducing other respiratory viruses, such as influenza. With fewer restrictions currently in place, influenza is slowly returning. In the meantime, people who are still suffering from long-COVID could be more vulnerable to an influenza virus infection and could develop a more severe influenza disease. This study provides directions to the effect of a previous SARS-CoV-2 exposure on influenza disease severity in a ferret model. This model is highly valuable to test sequential infections under controlled settings for translation to humans. We could not induce clear long-term COVID-19 effects, as the SARS-CoV-2 infections in the ferrets were mild. However, we still observed a slight increase in influenza disease severity compared to ferrets that had not encountered SARS-CoV-2 before. Therefore, it may be advisable to include long-COVID patients as a risk group for influenza vaccination.

[1]  O. J. Peter,et al.  Nonlinear optimal control strategies for a mathematical model of COVID-19 and influenza co-infection , 2022, Physica A: Statistical Mechanics and its Applications.

[2]  R. Plemper,et al.  SARS-CoV-2 variant of concern type and biological sex affect efficacy of molnupiravir in dwarf hamster model of severe COVID-19 , 2022, bioRxiv.

[3]  P. Shah,et al.  Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease , 2022, Immunity.

[4]  B. Hoffmann,et al.  Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta , 2021, Nature.

[5]  T. Ross,et al.  SARS-CoV-2 and Influenza A Virus Coinfections in Ferrets , 2021, Journal of virology.

[6]  H. Li,et al.  Immune signatures underlying post-acute COVID-19 lung sequelae , 2021, Science Immunology.

[7]  Youliang Wang,et al.  In vivo structure and dynamics of the SARS-CoV-2 RNA genome , 2021, Nature Communications.

[8]  Soo-Young Lee,et al.  The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2 , 2021, Biochemical and Biophysical Research Communications.

[9]  M. Netea,et al.  Induction of trained immunity by influenza vaccination - impact on COVID-19 , 2021, medRxiv.

[10]  J. Geddes,et al.  Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19 , 2021, PLoS medicine.

[11]  R. Scheuermann,et al.  Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals , 2021, Cell Reports Medicine.

[12]  P. Roholl,et al.  Pathology and Immunity After SARS-CoV-2 Infection in Male Ferrets Is Affected by Age and Inoculation Route , 2021, bioRxiv.

[13]  Zhongjie Li,et al.  Impact of COVID-19 outbreaks and interventions on influenza in China and the United States , 2021, Nature Communications.

[14]  B. Cong,et al.  Sequential infection with H1N1 and SARS-CoV-2 aggravated COVID-19 pathogenesis in a mammalian model, and co-vaccination as an effective method of prevention of COVID-19 and influenza , 2021, Signal Transduction and Targeted Therapy.

[15]  K. Laurie,et al.  Which influenza viruses will emerge following the SARS‐CoV‐2 pandemic? , 2021, Influenza and other respiratory viruses.

[16]  P. Moore,et al.  Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant , 2021, bioRxiv.

[17]  J. Min,et al.  SARS-CoV-2 cell tropism and multiorgan infection , 2021, Cell discovery.

[18]  H. Jäck,et al.  SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies , 2021, Cell.

[19]  Yu Chen,et al.  Coinfection with influenza A virus enhances SARS-CoV-2 infectivity , 2021, Cell Research.

[20]  E. Miska,et al.  In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs , 2021, Cell.

[21]  H. Achdout,et al.  Increased lethality in influenza and SARS-CoV-2 coinfection is prevented by influenza immunity but not SARS-CoV-2 immunity , 2021, Nature Communications.

[22]  C. Turner,et al.  Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity , 2021, Nature Communications.

[23]  I. Brown,et al.  Intranasal Infection of Ferrets with SARS-CoV-2 as a Model for Asymptomatic Human Infection , 2021, Viruses.

[24]  Jing Li,et al.  H1N1 exposure during the convalescent stage of SARS-CoV-2 infection results in enhanced lung pathologic damage in hACE2 transgenic mice , 2021, Emerging microbes & infections.

[25]  K. To,et al.  Coinfection by Severe Acute Respiratory Syndrome Coronavirus 2 and Influenza A(H1N1)pdm09 Virus Enhances the Severity of Pneumonia in Golden Syrian Hamsters , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  T. Clark,et al.  Physical distancing in schools for SARS-CoV-2 and the resurgence of rhinovirus , 2020, The Lancet Respiratory Medicine.

[27]  Lisa E. Gralinski,et al.  Animal models for COVID-19 , 2020, Nature.

[28]  J. Greenbaum,et al.  Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity , 2020, Cell.

[29]  Balraj Singh,et al.  COVID-19 and Influenza Co-Infection: Report of Three Cases , 2020, Cureus.

[30]  H. Ghasemzadeh-moghaddam,et al.  High prevalence of SARS‐CoV‐2 and influenza A virus (H1N1) coinfection in dead patients in Northeastern Iran , 2020, Journal of medical virology.

[31]  Angelo Carfì,et al.  Persistent Symptoms in Patients After Acute COVID-19. , 2020, JAMA.

[32]  Morten Nielsen,et al.  Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.

[33]  Ji Yeun Kim,et al.  SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity , 2020, The American journal of tropical medicine and hygiene.

[34]  P. Zhou,et al.  The epidemiology and clinical characteristics of co‐infection of SARS‐CoV‐2 and influenza viruses in patients during COVID‐19 outbreak , 2020, Journal of medical virology.

[35]  M. V. von Herrath,et al.  Faculty Opinions recommendation of Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[36]  R. Ozaras,et al.  Influenza and COVID‐19 coinfection: Report of six cases and review of the literature , 2020, Journal of medical virology.

[37]  Salvatore Ercolano,et al.  The Efficacy of Lockdown Against COVID-19: A Cross-Country Panel Analysis , 2020, Applied Health Economics and Health Policy.

[38]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[39]  H. Abad,et al.  Co‐infection with COVID‐19 and influenza A virus in two died patients with acute respiratory syndrome, Bojnurd, Iran , 2020, Journal of medical virology.

[40]  Hong Xu,et al.  Non-pharmaceutical interventions used for COVID-19 had a major impact on reducing influenza in China in 2020 , 2020, Journal of travel medicine.

[41]  M. Koopmans,et al.  SARS-CoV-2 is transmitted via contact and via the air between ferrets , 2020, bioRxiv.

[42]  Baoying Huang,et al.  Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2 , 2020, Science.

[43]  Eun-Ha Kim,et al.  Infection and Rapid Transmission of SARS-CoV-2 in Ferrets , 2020, Cell Host & Microbe.

[44]  Q. Ding,et al.  The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China , 2020, Journal of medical virology.

[45]  R. Xavier,et al.  Defining trained immunity and its role in health and disease , 2020, Nature Reviews Immunology.

[46]  Wenling Wang,et al.  The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice , 2020, Nature.

[47]  Victor M Corman,et al.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[48]  V. von Messling,et al.  Ferret models of viral pathogenesis , 2015, Virology.

[49]  A. Gruber,et al.  Influenza A Viruses Target Type II Pneumocytes in the Human Lung , 2012, The Journal of infectious diseases.

[50]  R. Rappuoli,et al.  Efficacy of Vaccination with Different Combinations of MF59-Adjuvanted and Nonadjuvanted Seasonal and Pandemic Influenza Vaccines against Pandemic H1N1 (2009) Influenza Virus Infection in Ferrets , 2011, Journal of Virology.